U.S. markets closed
  • S&P Futures

    3,647.00
    +23.75 (+0.66%)
     
  • Dow Futures

    29,785.00
    +156.00 (+0.53%)
     
  • Nasdaq Futures

    12,375.50
    +98.50 (+0.80%)
     
  • Russell 2000 Futures

    1,836.70
    +16.60 (+0.91%)
     
  • Crude Oil

    45.06
    -0.28 (-0.62%)
     
  • Gold

    1,783.40
    +2.50 (+0.14%)
     
  • Silver

    22.74
    +0.14 (+0.63%)
     
  • EUR/USD

    1.1953
    +0.0019 (+0.16%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3346
    +0.0014 (+0.11%)
     
  • USD/JPY

    104.3400
    +0.0160 (+0.02%)
     
  • BTC-USD

    19,571.73
    +74.88 (+0.38%)
     
  • CMC Crypto 200

    384.57
    +19.98 (+5.48%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,791.24
    +357.62 (+1.35%)
     

Infinity to Present at Upcoming Investor Conferences in September

·2 min read

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that management will be participating in the following investor conferences this month:

Wells Fargo Securities Annual Healthcare Conference

Date:

Wednesday, September 9th

Time:

3:30 pm Eastern Time

Webcast:

https://metroconnections.zoom.us/webinar/register/WN_wfeVRxPWSNi48O-IjQSqVQ

H.C. Wainwright Global Investment Conference

Date:

Tuesday, September 15th

Time:

2:00 pm Eastern Time

Webcast:

https://wsw.com/webcast/hcw7/infi/1595926

A live webcast of each presentation will be available on the Investors/Media section of Infinity's website at www.infi.com and will be available for 30 days following the event.

About Infinity and Eganelisib

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus AB928 (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol-Myers Squibb.
Tecentriq® and Avastin® are registered trademarks of Roche.
Abraxane® is a registered trademark of Celgene.
Doxil® is a registered trademark of Janssen Products.
Copiktra® is a registered trademark of Verastem, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005143/en/

Contacts

Investor Relations:
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com